Kairos Pharma (KAPA) Investor presentation summary

Mission and strategic focus

• Dedicated to advancing therapies that address cancer drug resistance and immune suppression challenges.

• Focus on innovative cancer therapeutics using new technologies to reverse resistance and immune suppression.

Lead programs and clinical pipeline

• ENV105, an antibody targeting CD105, is in Phase 2 for castrate-resistant prostate cancer and Phase 1 for EGFR-driven lung cancer.

• KROS 201, an activated T cell therapy, has cleared IND for glioblastoma.

• KROS 741, a small molecule CMET antagonist, is initiating Phase 1 for biomarker-driven lung and esophageal-gastric cancers.

• Additional preclinical assets target cancer growth, immune evasion, and muscle wasting.

Clinical trial highlights and efficacy data

• ENV105 restores sensitivity to hormone and EGFR therapies, showing tumor volume reduction in preclinical and clinical models.

• Phase 2 prostate cancer trial (NCT03418324, NCT05534646) shows stable disease in most patients and a median PFS of 13.7 months.

• ENV105 is being tested in combination with radiation and alpha-emitting isotopes for enhanced efficacy.

• Phase 1 lung cancer trial (NCT05401110) is accruing patients resistant or partially responsive to Tagrisso.